Fig. 1: iASPP unexpectedly suppresses oncogenic KRAS-driven PC onset.
From: p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
A Percentage of mice with evidence of tumour (pancreatic, visceral, or subcutaneous; excluding lymphoma) from the KC (n = 103) and KC;iASPPΔ8/Δ8 (n = 81) overall survival cohort. **** = p < 0.0001; n.s. = not significant; Fisher’s exact test. B Kaplan-Meier pancreatic tumour free survival of KC and KC;iASPPΔ8/Δ8 mice in the overall survival cohort. Number of mice and median survival for tumour-bearing mice with non-pancreatic tumour bearing mice censored. **** = p < 0.0001, log-rank test. N = , number of mice; m.s., median survival. C Pancreatic cancer at 6 weeks in KC;iASPPΔ8/Δ8 mouse. Upper image, dissected pancreas with attached duodenum. Middle image, whole pancreas HE stained. Bottom left image, well-differentiated HE stained PC. Bottom right image, IHC stained with cytokeratin 8 to demonstrate epithelial original. Middle image scale bar, 1 mm. Bottom images scale bar, 50 µm. Duodenum is denoted by black triangle and PC is denoted asterisk. D Percentage of extra-pancreatic tumours that are either lung or liver in the KC and KC;iASPPΔ8/Δ8 survival cohort. * = p < 0.05; n.s., not significant; Fisher’s exact test. E Percentage of primary pancreatic tumours in which the cancer is either predominantly well- or poorly-differentiated in the KC and KC;iASPPΔ8/Δ8 survival cohort. ** = p < 0.01; Fisher’s exact test.
